Influenza 5xM2e mRNA lipid nanoparticle vaccine confers broad immunity and significantly enhances the efficacy of inactivated split vaccination when coadministered
The Journal of Immunology · 01.01.2025 · 214 (1) · 104-114
DOI: 10.1093/jimmun/vkae013 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 31.01.2025. Verfasst von Phillip Grovenstein und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, United States. Hauptthemen laut MEDLINE: Influenza Vaccines, Nanoparticles, Orthomyxoviridae Infections, Viral Matrix Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH, NIAID.
Abstract (Originalsprache)
Current influenza vaccines are not effective in conferring protection against antigenic variants and pandemics. To improve cross-protection of influenza vaccination, we developed a 5xM2e messenger RNA (mRNA) vaccine encoding the tandem repeat conserved ectodomain (M2e) of ion channel protein M2 derived from human, swine, and avian influenza A viruses. The lipid nanoparticle (LNP)–encapsulated 5xM2e mRNA vaccine was immunogenic, eliciting high levels of M2e-specific IgG antibodies, IFN-γ+ T cells, T follicular helper cells, germinal center phenotypic B cells, and plasma cells. The mice with 5xM2e mRNA vaccination were broadly protected against lethal infection regardless of hemagglutinin (H1, H3, H5) subtypes by preventing severe weight loss. Injection of 5xM2e mRNA LNP vaccine induced acute innate responses recruiting monocytes, macrophages, and diverse subsets of dendritic cells. A single dose of combined 5xM2e mRNA LNP and split vaccines resulted in significantly enhanced and sustainable IgG antibody responses to viral antigens and protection against homologous and heterologous viruses. This study provides a new strategy of combined mRNA and seasonal vaccination, significantly enhancing vaccine protective efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, United States.
ORCID-Profile: Phillip Grovenstein, Noopur Bhatnagar, Chau Thuy Tien Le, Chong Hyun Shin, Lanying Du, Jeeva Subbiah
Förderung
- NIAID NIH HHS
- NIH
- NIAID
Zitieren
APA
Grovenstein, P., Bhatnagar, N., Kim, K. H., Pal, S. S., Le, C. T. T., Raha, J. R., Liu, R., Shin, C. H., Park, B. R., Du, L., Subbiah, J., Wang, B. Z., & Kang, S. M. (2025). Influenza 5xM2e mRNA lipid nanoparticle vaccine confers broad immunity and significantly enhances the efficacy of inactivated split vaccination when coadministered. The Journal of Immunology, 214(1), 104-114. https://doi.org/10.1093/jimmun/vkae013
Vancouver
Grovenstein P, Bhatnagar N, Kim KH, Pal SS, Le CTT, Raha JR, et al. Influenza 5xM2e mRNA lipid nanoparticle vaccine confers broad immunity and significantly enhances the efficacy of inactivated split vaccination when coadministered. The Journal of Immunology. 2025;214(1):104-114. doi:10.1093/jimmun/vkae013
BibTeX
@article{Grovenstein2025,
author = {Grovenstein, Phillip and Bhatnagar, Noopur and Kim, Ki-Hye and Pal, Surya Sekhar and Le, Chau Thuy Tien and Raha, Jannatul Ruhan and Liu, Rong and Shin, Chong Hyun and Park, Bo Ryoung and Du, Lanying and Subbiah, Jeeva and Wang, Bao-Zhong and Kang, Sang-Moo},
title = {Influenza 5xM2e mRNA lipid nanoparticle vaccine confers broad immunity and significantly enhances the efficacy of inactivated split vaccination when coadministered},
journal = {The Journal of Immunology},
year = {2025},
volume = {214},
number = {1},
pages = {104--114},
doi = {10.1093/jimmun/vkae013}
}
EUVIMED